Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (581-590 of 610) with videos related to

Pageof 61
Sort By:
ESMO Open|May 22, 2025
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancerD Mahalingam, A Saeed, S F Powell, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Biopreservation and Biobanking|May 22, 2014
Development and progress of Ireland's biobank network: Ethical, legal, and social implications (ELSI), standardized documentation, sample and data release, and international perspectiveBlanaid Mee, Eoin Gaffney, Sharon A Glynn, et al.
Blood|March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
Antioxidants (Basel, Switzerland)|July 29, 2023
Role of Enzymic Antioxidants in Mediating Oxidative Stress and Contrasting Wound Healing Capabilities in Oral Mucosal/Skin Fibroblasts and TissuesParkash Lohana, Albert Suryaprawira, Emma L Woods, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
JCI Insight|September 20, 2019
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNKAmber J Giles, Shuyu Hao, Michelle Padget, et al.
Molecular Cancer Therapeutics|April 5, 2012
Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screeningRichard J Rickles, Winnie F Tam, Thomas P Giordano, et al.
Leukemia|February 21, 2017
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom studyA Hochhaus, T Masszi, F J Giles, et al.
Pageof 61

Showing results (581-590 of 610) with videos related to

Sort By:
Pageof 61
ESMO Open|May 22, 2025
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancerD Mahalingam, A Saeed, S F Powell, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Biopreservation and Biobanking|May 22, 2014
Development and progress of Ireland's biobank network: Ethical, legal, and social implications (ELSI), standardized documentation, sample and data release, and international perspectiveBlanaid Mee, Eoin Gaffney, Sharon A Glynn, et al.
Blood|March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
Antioxidants (Basel, Switzerland)|July 29, 2023
Role of Enzymic Antioxidants in Mediating Oxidative Stress and Contrasting Wound Healing Capabilities in Oral Mucosal/Skin Fibroblasts and TissuesParkash Lohana, Albert Suryaprawira, Emma L Woods, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
JCI Insight|September 20, 2019
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNKAmber J Giles, Shuyu Hao, Michelle Padget, et al.
Molecular Cancer Therapeutics|April 5, 2012
Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screeningRichard J Rickles, Winnie F Tam, Thomas P Giordano, et al.
Leukemia|February 21, 2017
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom studyA Hochhaus, T Masszi, F J Giles, et al.
Pageof 61